Bioarchitech's journey from its beginning to its departure from the BioEscalator has been characterised by strategic growth and adaptability. In 2019, the company began its residency at the BioEscalator, collaborating with the University of Oxford and Cancer Research UK (CRUK). By 2021, despite the challenges posed by the pandemic, Bioarchitech successfully raised funds and undertook partnerships with biotech companies in Europe and the US.
The company's exit from the BioEscalator exemplifies the end of a significant chapter. The close-knit team of four full-time employees has been an integral part of the BioEscalator community, consistently supporting and collaborating with fellow innovators. While Bioarchitech will be missed as a substantial presence at the BioEscalator, they will be relocating just down the road to their new space at the Wood Centre for Innovation. The BioEscalator team looks forward to continuing its relationship with the company.
Kevin Maskell, CSO of Bioarchitech, reflects on the impact of their time at the BioEscalator: "Being a BioEscalator tenant offered us unique opportunities for collaboration. The open and collaborative interactions with other tenants and the BioEscalator team have been invaluable. We have had access to flexible lab space, equipment, and expertise at the University of Oxford, which has added significant value to our work. For example, consulting with a team of oncologists and other surgeons was easy when we wanted to explore a new therapeutic approach. This kind of input is usually out of reach for small companies, but being located here has provided us with incredible support."
As Bioarchitech moves to its new location, the BioEscalator eagerly anticipates the continued impact of its groundbreaking work in cancer therapy.